The Lost Crown, a 2D action-adventure platformer Metroidvania developed by Ubisoft Montpellier. Manipulate time and space on ...

In a report released today, Ben Shelley from UBS maintained a Hold rating on UBISOFT Entertainment (0NVL – Research Report), with a price ...

Analyst Aleksander Peterc from Bernstein maintained a Hold rating on UBISOFT Entertainment (0NVL – Research Report) and keeping the price ...

Internal game development spending at Ubisoft has steadily increased over the past five years, hitting EUR 1 billion in fiscal 2023, nearly double the amount in fiscal 2018. Yet, net bookings over the ...

If you're feeling like the Olympic mixed doubles curling trials are earlier than usual, that's because they are. In a move to better prepare Canadians curlers for the Olympics, Curling Canada has ...

So far, Novartis has only guided investors to expect results in 2025, but a federal trials database lists the primary completion in late May. — Ned Pagliarulo Entyvio, an injectable drug for ...

Despite the mixed reception to Ubisoft's video game offerings, there's no denying that the studio has let players enjoy some of the greatest action-packed games ever made. The heights reached by ...

Ubisoft's continuous string of failures was due to their subpar games with many in-game microtransactions. Most of the games released this year did not perform well due to a lack of creativity and ...

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. Chemotherapy followed by hormone therapy is often used after surgery for breast cancer to ...

A US judge has delayed a trial for the suspect in the second assassination attempt of President-elect Donald Trump until September 2025, according to a court order. Lawyers for the suspect, Ryan ...

NBC News' Vaughn Hillyard takes a look back at Donald Trump's legal battles, the status of each of his cases and how the indictments help shape the narrative of his re-election.Dec. 23, 2024 ...

According to GlobalData’s Pharmaceutical Intelligence Centre, most trials completed in 2024 were Phase I studies (40.92%), with the second highest completion in Phase II (36.28%). During 2024, 15.62% ...